Urine test ‘could help spot recurring kidney cancer’, researchers suggest - The study found the urine test correctly detected ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory ...

Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and ...

(Alliance News) - Hutchmed China Ltd on Wednesday hailed results of a clinical trial evaluating its kidney cancer treatment in China, while it reported an annual revenue dive. The Hong Kong-based ...

Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial ...

The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side ...

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in ...

PSMA may be a noninvasive biomarker for predicting treatment response in metastatic clear cell renal cell carcinoma (RCC).